Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZQORV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DEC008
|
|||||
| Synonyms |
DEC008; mMUC16-CPT113; HWK-016
Click to Show/Hide
|
|||||
| Organization |
WuXi Biologics (Originator);Hangzhou DAC Biotechnology (DAC Biotech) (Originator);Whitehawk Therapeutics
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Mucin-16 (MUC16)
|
Antigen Info | ||||
| Payload Name |
CPT113
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The indication landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Ovarian cancer |
1 Trials
|
|||||
| Endometrial cancer |
1 Trials
|
|||||
| Prostate cancer |
1 Trials
|